Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

multidrug resistant infections

- PMLiVE

Valeant takeover bid for Allergan turns hostile

Canadian firm goes directly to shareholders with offer

AZ expands its mHealth services with new COPD initiative

Partners with Exco InTouch to launch Me&MyCOPD programme

- PMLiVE

UCB taps EU for €75m in R&D funding

Agrees innovative risk-sharing finance deal with European Investment Bank

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

AstraZeneca has clearer route to Movantik approval in US

Won't have to carry out cardiovascular outcomes study prior to approval

- PMLiVE

AZ licenses asthma infection drug from Synairgen

Boosts respiratory portfolio with $232m deal

- PMLiVE

Allergan rebuffs Valeant once again

Could lead to hostile takeover bid

- PMLiVE

AstraZeneca backs mental health campaign

Pharma company supports Mental Health America

- PMLiVE

ASCO: AstraZeneca shows off cancer immunotherapy

MEDI4736 could rival Merck & Co’s anti-PD1 inhibitor pembrolizumab

- PMLiVE

FDA fast-tracks new AstraZeneca antibiotic

Speeds up review period for AZD0914 in gonorrhoea

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

Valeant steps up pressure on Allergan with raised bid

Ups price yet again in attempt to acquire company behind Botox

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links